P RADER-WILLI SYNDROME (PWS) is a genetic disorder, in the majority of subjects caused by either a microdeletion on the paternally derived chromosome 15q11-13 or a uniparental maternal disomy affecting the same region. In approximately 1-5%, PWS is the result of an imprinting center mutation, which results in silencing of genes that are normally active only in the paternally inherited chromosome 15q11-13 (1, 2) . PWS is characterized by a number of signs and symptoms, including hypotonia, psychomotor delay, short stature, and obesity.
Children with PWS have an abnormal body composition, even when they have a normal body weight, with a relatively high body fat percentage and a low lean body mass (3, 4) . As a group, euglycemic PWS individuals have lower fasting insulin and higher insulin sensitivity than a weight-comparable group (5) (6) (7) (8) (9) . Suggested mechanisms for the higher insulin sensitivity are GH deficiency (10) and an abnormal body fat distribution, compared with simple obesity, as described in PWS female adults (11) . In these PWS women, insulin sensitivity was higher and hepatic insulin extraction was increased, compared with women with simple obesity. Nevertheless, a subgroup of PWS individuals does develop insulin resistance and the absolute prevalence of non-insulindependent diabetes mellitus in PWS subjects over the age of 20 yr is high (12) . A familial component in insulin resistance, as in non-PWS subjects, might also contribute in PWS subjects (12) .
Adiponectin is an antiinflammatory adipocytokine that has been inversely related to adiposity and insulin resistance (13) (14) (15) (16) , and is thought to be protective with regard to diabetes mellitus and cardiovascular disease (17) . Adiponectin levels increase during weight loss (18) . Adiponectin levels in obese adults with PWS are high, compared with simple obesity (19 -22) , and low (19, 22) or similar (21) compared with lean adult controls. So far, no published data concerning adiponectin levels in prepubertal, not severely overweight PWS children, compared with normal-weight healthy controls, are available.
Because body fat, more than body mass index per se, is reported to be inversely related to adiponectin (23), we hypothesized that adiponectin levels would be low in PWS children, compared with healthy sex-and age matched children, due to their expected relatively high body fat percentage, although the counteraction of their low insulin levels might result in normal adiponectin levels. GH treatment might have a dual effect on adiponectin levels. GH is known to decrease body fat percentage, which would increase adiponectin levels. On the other hand, GH treatment has also been associated with lower insulin sensitivity (24) . We hypothesized that the effects of GH on insulin sensitivity would be superior and therefore that adiponectin levels would decrease. The aim of the present study was to evaluate the following: 1) serum adiponectin levels, measures of body composition and body fat distribution, carbohydrate metabolism, and triglyceride levels; 2) the associations between these parameters; and 3) the effects of GH treatment on these parameters, compared with randomized controls in prepubertal, generally not overweight PWS children.
Patients and Methods Patients
Twenty PWS children were evaluated for the present study. These children were all enrolled in a randomized, controlled trial to investigate the effects of GH treatment on growth, body composition, activity level, and psychosocial development. They fulfilled the following inclusion criteria: 1) genetically confirmed diagnosis of PWS; 2) age between 4 and 9 yr at start of study; 3) prepubertal, defined as Tanner breast stage 1 for girls and testicular volume less than 4 ml for boys (25) , both before and during the study. Most children were regularly seen by a dietitian and a physiotherapist. The caloric intake and activity level of all children were standardized at 3 months before study, and recommendations were given. Compliance to diet and exercise was evaluated by the research nurse, in close collaboration with the dietitian and, if indicated, the physiotherapist. All children were naïve to GH treatment at the start of study. They were included irrespective of their GH status. After stratification for age and body mass index (BMI) [Ͻ2 sd score (SDS) vs. Ͼ2 SDS], children were randomized into either the GH group or the control group. For 2 yr, children of the GH group (n ϭ 10) were treated with 1 mg Genotropin (somatropin) per square meter sc daily (during the first 4 wk they received 0.5 mg/m 2 ⅐d to avoid fluid retention), and children of the control group (n ϭ 10) were not treated with GH. After 2 yr, the control group also started GH treatment. At the start of study, reimbursement for GH treatment in Dutch PWS children had not yet been approved. Because there was a lack of controlled data with respect to GH treatment in PWS, a controlled study was considered ethical by the Dutch Advisory Board on GH in children and the Medical Ethics Committee, and the study protocol was approved by the Medical Ethics Committee of Erasmus Medical Centre, Rotterdam, The Netherlands. Written informed consent was obtained from the parents.
Methods
Anthropometry. At baseline and after 1 and 2 yr of GH treatment or follow-up in the control group, standing height (or supine length, when appropriate) and weight were measured and BMI was calculated. Height and BMI were expressed as SDS, adjusting for age and sex, according to Dutch reference data for children (26, 27) . We defined overweight as a BMI greater than ϩ2 SDS. BMI, height SDS, and BMI SDS were calculated with Growthanalyser (version 3.0; www.growthanalyser.org).
Body composition. Dual energy x-ray absorptiometry (DXA type Lunar Prodigy; GE Healthcare, Chalfont St. Giles, UK) was performed in all children, and total fat mass, fat percentage, lean body mass (LBM), and fat of the trunk region were measured. The trunk region consisted of chest, abdomen, and pelvis. The trunk fat to total fat ratio was considered as estimate for fat distribution. Fat mass, fat percentage, and LBM were transformed into SDS adjusting for sex and age, using Dutch reference values for children (28) .
Collection of blood. Blood samples were collected in the morning after a 12-h overnight fast, immediately centrifuged, and stored at Ϫ20 C until assayed.
Assays
Each assay was performed in the same laboratory. Serum glucose and triglyceride levels were assessed on Abbott Architect clinical chemistry analyzer (Abbott Laboratories, Irving, TX). The intra-and interassay coefficients of variation (CVs) were, respectively, 0.7 and 0.8% for glucose and 0.5 and 0.6% for triglycerides. Serum insulin levels were measured by immunoradiometric assay (Medgenix; Biosource Europe, Fleurus, Belgium). Fasting normal range was less than 15 mU/liter (manufacturer's information). The intraassay CV was 2-4.7% and the interassay CV was 4.2-11.3%. The minimal detectable dose (MDD) was 1 mU/liter, and no cross-reactivity with proinsulin was observed. Assessment of insulin resistance was calculated using the homeostasis model assessment (HOMA) as previously described (29, 30) . Serum adiponectin levels were assessed in duplicate by an ELISA (R&D Systems Inc., Minneapolis, MN). The intraassay CV was less than 7%, and the interassay CV was less than 7%. The MDD was 0.246 ng/ml, and no significant cross-reactivity or interference was observed. Adiponectin control values were obtained from 40 healthy prepubertal children with normal height and BMI (23 boys, 17 girls), aged 5.0 -10.2 yr, and attending the outpatient clinic for a minor surgical procedure. Children suffering from any systemic illness, syndrome, or dysmorphic feature were excluded. Normal height and BMI were defined as height and BMI between Ϫ2 SDS and ϩ2 SDS, according to Dutch standards. The reference study was approved by the Medical Ethics Committee of Erasmus Medical Center, Rotterdam, The Netherlands, and written informed consent was obtained from the parents. Serum IGF-I and IGF-binding protein (IGFBP)-3 were measured using a specific RIA in one laboratory (31) . The intraassay CV was 4% and the interassay CV was 6%. The MDD for IGF-I was 6.0 ng/ml and for IGFBP-3 0.002 mg/liter, and no significant cross-reactivity or interference was observed. For IGF-I and IGFBP-3, sex-and age-matched references were available obtained from a healthy Dutch population. This reference study was approved by the Medical Ethics Committee of Wilhelmina's Children's Hospital Utrecht (The Netherlands), and written informed consent was obtained from the parents. Because of the age and sex dependency, IGF-I and IGFBP-3 levels were transformed into SDS.
Statistics
Statistical analysis was performed by the Statistical Package for Social Sciences (version 11.0; SPSS, Chicago, IL). Most of our data were not Gaussian distributed. We therefore expressed data as median [interquartile range (iqr)] and we used nonparametric tests. Differences, compared with baseline within groups, were calculated using Wilcoxon signed rank test. Differences in changes, compared with baseline between the GH and control groups, were calculated with Mann Whitney U tests. Afterward we used Bonferroni's correction for multiple testing for both inter-and intraindividual testing. Correlations were calculated by partial correlation coefficient, adjusting for age and sex. We compared the adiponectin levels of PWS children with reference data of healthy sex-and age-matched controls (n ϭ 40) with Wilcoxon signed rank test.
Results

Clinical characteristics
Clinical characteristics of the study group are listed in Table 1 . All children had a genetically confirmed diagnosis of PWS. Six children had a paternal deletion, five had a uniparental maternal disomy, two had an imprinting center mutation, and in seven PWS was confirmed by a positive methylation test, but the underlying genetic defect was yet unknown. There was no significant difference between age, height, or BMI of both groups at the start of the study. The median (iqr) BMI at start of study was 0.8 SDS (0.1-1.2) in the GH group and 1.1 SDS (0.6 -1.5) in the control group. Only two children were considered overweight, at the start of the study, defined as BMI greater than ϩ2 SDS (one patient in the GH group and one in the control group). Median (iqr) height SDS increased significantly during the first and the second year of GH treatment from Ϫ2.2 (Ϫ3.1 to Ϫ1.8) to Ϫ1.3 (Ϫ1.7 to Ϫ0.8) (P Ͻ 0.05) to Ϫ0.6 (Ϫ0.9 to Ϫ0.3) (P Ͻ 0.05) but remained low in the control group [from Ϫ2.8 (Ϫ3.4 to 7.8) to Ϫ2.8 (Ϫ3.5 to Ϫ2.0) to Ϫ3.0 (Ϫ3.5 to Ϫ1.8)]. BMI tended to decrease in the GH group during the first year, resulting in a significantly greater decrease in BMI SDS, compared with baseline, in the GH group than the control group after 1 yr of study (P Ͻ 0.05).
Adiponectin
Adiponectin levels are presented in Fig. 1 and Table 2 . At baseline, adiponectin levels were significantly higher in the total group of PWS children [17.1 mg/liter (13.9 -23.2)], compared with healthy age-and sex-matched controls [11.8 mg/ liter (9.7-12.5), P Ͻ 0.005]. During GH treatment, median (iqr) adiponectin significantly increased from 15.9 g/ml (13.3-23.9) to 24.7 g/ml (15.0 -25.9) (P Ͻ 0.05) to 24.6 g/ml (15.4 -28.2) (P Ͻ 0.05) after 1 and 2 yr, respectively. In the control group, adiponectin levels did not change significantly during the study [from 17.1 g/ml (13.1-23.1) to 13.4 g/ml (11.6 -21.4) to 15.8 g/ml (12.5-19.2]. During 2 yr, the increase in adiponectin was significantly greater in the GH group than the control group (P Ͻ 0.05).
Body composition
Body composition of the study groups is presented in Table 3 . Median LBM increased significantly, during 2 yr of GH treatment, compared with baseline from Ϫ2.2 SDS (Ϫ2.7 to Ϫ2.0) to Ϫ1.6 SDS (Ϫ1.9 to Ϫ1.4) (P Ͻ 0.05) to Ϫ1.2 SDS (Ϫ1.7 to Ϫ1.1) (P Ͻ 0.05). In the control group, LBM SDS decreased, compared with baseline, from Ϫ2.3 SDS (Ϫ2.8 to Ϫ1.8) to Ϫ2.5 (Ϫ3.0 to Ϫ1.8) to Ϫ2.8 SDS (Ϫ3.3 to Ϫ1.9) (P Ͻ 0.05 after 2 yr). Body fat percentage decreased during the first year of GH treatment from 1.7 SDS (1.6 -2.0) to 1.4 SDS (0.9 -1.7) (P Ͻ 0.05) and increased during the second year to 1.7 SDS (0.9 -1.9). In contrast, in the control group, body fat percentage increased significantly over time from 1.8 SDS (1.5-2.4) to 2.1 SDS (1.8 -2.2) to 2.1 SDS (1.9 -2.4) (P Ͻ 0.05 after 2 yr). Trunk fat to total fat ratio tended to decrease, compared with baseline, during the first year of GH treatment (P ϭ 0.06). After 24 months of GH treatment, the trunk fat to total fat ratio was not significantly lower than at baseline (P ϭ 0.12).
Fasting insulin, glucose, and triglyceride levels
Median fasting insulin and glucose levels, the insulin glucose ratio, and the HOMA index as a measure of insulin resistance (HOMA-IR) were within normal range for the total Dark gray bars represent GH-treated PWS children, white bars non-GH-treated PWS children, and gray bars age-and sexmatched healthy controls. 1, P Ͻ 0.05, adiponectin levels, compared with baseline levels. Changes in adiponectin levels from baseline are significantly greater in the GH group, compared with the randomized PWS control group after 12 (P Ͻ 0.001) and 24 months (P Ͻ 0.001). PWS children had significantly higher adiponectin levels than healthy sex-and age-matched controls (P Ͻ 0.005). *, Healthy sexand age-matched controls.
group ( Table 2 ). The change after 1 and 2 yr of study was not significantly different between the GH group and the control group. In the GH group, fasting insulin levels and insulin to glucose ratio increased significantly during the first year (P Ͻ 0.05) but returned to baseline during the second year. In contrast, in the control group, fasting insulin levels, insulin to glucose ratio, and HOMA-IR had significantly increased after 2 yr, compared with baseline (P Ͻ 0.05). All children of the GH group had insulin and glucose levels, insulin to glucose ratio, and HOMA-IR within the normal range during the entire study. In contrast, three children of the control group had fasting insulin levels above the upper limit of normal after 2 yr of study (range, 19 -31 mU/liter). Fasting triglycerides at the start were above normal range in three of 20 children (15%) (two children of the GH group and one of the control group). Of the two overweight PWS children at the start of study, one had increased serum triglycerides.
IGF-I and IGFBP-3 levels
IGF-I and IGFBP-3 levels were low, compared with normal, in our PWS children. During 2 yr of GH treatment, IGF-I SDS increased significantly from Ϫ1.7 (Ϫ2.2 to Ϫ1.2) to 2.3 (1.6 -3.0) (P Ͻ 0.05) to 2.3 (2.1-2.9) (P Ͻ 0.05) and IGFBP-3 SDS from Ϫ2.0 (Ϫ3.0 to Ϫ1.3) to 0.5 (Ϫ0.1 to 1.0) (P Ͻ 0.05) to 0.6 (0.4 -1.1) (P Ͻ 0.05), but IGF-I and IGFBP-3 remained low in the control group.
Associations between adiponectin and body composition, triglyceride levels, and carbohydrate metabolism
Results of correlations between serum adiponectin levels, body composition and body fat distribution, carbohydrate metabolism, and circulating triglycerides, after adjustment for age and sex, are listed in Table 4 . There was a significant inverse relation between adiponectin and triglyceride levels (r ϭ Ϫ0.52, P ϭ 0.03). Although there was a tendency toward inverse relationships between adiponectin and BMI and body fat percentage, these did not reach statistical significance (P ϭ 0.08 and 0.07, respectively). Notably, no association was found between adiponectin levels and the HOMA-IR or insulin to glucose ratio (r ϭ Ϫ0.10, P ϭ 0.71). The increase in adiponectin levels after 2 yr of follow-up was strongly inversely correlated with the change in body fat percentage (r ϭ Ϫ0.81, P Ͻ 0.001), but there was no significant association between the increase in adiponectin levels and the change in triglyceride levels. Data are expressed as median (iqr). a P Ͻ 0.05, compared with baseline corrected for multiple testing. b P Ͻ 0.05, change compared with baseline in GH group vs. control group corrected for multiple testing. c P Ͻ 0.001, change compared with baseline in GH group vs. control group corrected for multiple testing. 
Discussion
Our study demonstrates high serum adiponectin levels in young, prepubertal, generally not overweight children with PWS, compared with healthy sex-and age-matched controls. Serum adiponectin levels related inversely with triglyceride levels. There was a tendency to an inverse relation between adiponectin and body fat percentage and BMI but no significant association between serum adiponectin levels and fasting insulin and glucose levels, insulin to glucose ratio, and HOMA-IR. During GH treatment, serum adiponectin levels increased significantly, compared with no change in the control group. The increase in adiponectin levels was strongly, inversely correlated with the change in body fat percentage. Fasting insulin and glucose levels, as well as insulin to glucose ratio, increased significantly during the first year of GH treatment but returned to baseline levels during the second year. In the control group, fasting insulin, insulin to glucose ratio, and HOMA-IR significantly increased over 2 yr, compared with baseline. This is the first report showing that young, prepubertal, not severely overweight PWS children have high serum adiponectin levels, compared with healthy sex-and agematched controls. Because the reported prevalence of noninsulin-dependent diabetes mellitus in individuals with PWS is high (12) , and body fat percentage in PWS is relatively high, we expected relatively low adiponectin levels. In previous studies in obese adults with PWS, serum adiponectin levels were high, compared with obese non-PWS controls (19 -22) , but compared with lean adult controls, adiponectin levels were low (19, 22) or similar (21) . Previous studies showed that, in PWS children and adults, insulin sensitivity is high (6, 10) , which might be due to a relatively low amount of visceral fat, compared with obese controls (11) . We postulate that, in addition to a relatively low amount of visceral fat, high adiponectin levels might contribute to the increased insulin sensitivity in PWS children.
We found no significant association between adiponectin levels and BMI and body fat percentage, although there was a tendency toward an inverse relationship. In healthy subjects, a negative association has been described (13) , but nowadays it is concluded that low adiponectin levels are more closely related to the degree of insulin resistance and hyperinsulinemia than to the degree of adipositas (16) . Also Hoybye et al. (22) reported the absence of a relationship between adiponectin and BMI in adult PWS patients. Our study did not show an association between adiponectin levels and trunk to total fat mass as measured by DXA. This was in contrast to our expectations, because previous studies showed that adiponectin concentrations correlated stronger with central adiposity than with overall adiposity (32) (33) (34) . The trunk to total fat mass ratio is, however, not a validated procedure for measuring visceral adipose tissue, which might explain the absence of the relation. It might also be that, particularly in PWS subjects, trunk to total fat is not a good measure for visceral fat. It has been shown in PWS women (11) that they had low visceral fat, as measured by magnetic resonance imaging, whereas measures of waist diameter, waist to hip ratio, waist to height ratio, or trunk/limb skinfold were similar to obese controls. This is most likely due to the fact that in PWS subjects, particularly the sc trunk fat, instead of the visceral fat, is high. These data strongly ask for more accurate measurements by magnetic resonance imaging of visceral fat vs. sc fat in PWS.
We found a significant inverse association between serum adiponectin and triglyceride levels in young PWS children. This is in line with findings in healthy obese and nonobese adolescents (35) . It might well be that adiponectin modulates insulin sensitivity by diminishing the accumulation of triglycerides in the skeletal muscle tissue, as was found in animal studies (36) .
We did not find a significant correlation between baseline adiponectin levels and insulin to glucose ratio or HOMA index, which is in contrast to previous findings in obese adults with PWS (20) . This discrepancy might be explained by the fact that insulin resistance and overweight were not yet present in our young PWS children. In healthy children, adiponectin correlated with body weight, BMI, waist, fasting glucose, and 30-min insulin, but the correlations were positive in boys and negative in girls, indicating that plasma adiponectin is not a simple marker of central fat and insulin sensitivity in children (37) . In our study, we did not find such sex differences (data not shown).
During the first year of GH treatment, adiponectin levels increased and remained at the same level during the second year. Also, body fat percentage, lean body mass, and IGF-I levels changed particularly during the first year. Based on these findings, the increase of adiponectin levels during GH treatment might reflect the decline in body fat percentage during GH treatment. The increase in LBM during GH treatment might also be related to the increased adiponectin levels. Because skeletal muscle is the primary tissue of insulinstimulated glucose uptake, disposal, and storage (38) , increased lean body mass might contribute to increased insulin sensitivity.
Insulin levels were normal at the start of the study. During the first year of GH treatment, insulin and glucose levels did increase, but levels returned to baseline after 2 yr. The high adiponectin levels in PWS children may contribute to the relatively low insulin levels because adiponectin is suggested to be protective against insulin resistance and diabetes mellitus (14, 15) . The high IGF-I levels after 2 yr of treatment indicate that children were compliant to GH treatment.
In conclusion, adiponectin levels are increased in young, prepubertal, not severely overweight PWS children. This is in line with the relatively high insulin sensitivity in PWS. 
